Sign in to view content

1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD

Robert L. Avery, MD

Video
Published 2025

Related

ADVM-022 Intravitreal Gene Therapy for Neovascular AMD: Phase 1 OPTIC Trial Update
Dante Joseph Pieramici, MD
Annual Meeting Talks
2022
Low rates of endophthalmitis with intravitreal aflibercept in real world Canadian practice - data from the large prospective study PEGASUS.
Michael Peter Fielden, MD, FRCS(C)
On Demand Cases, Courses, and Papers
2019
Abicipar Phase 2 MAPLE Trial: Evaluation of All Patients With Post-Injection Inflammation
Tarek S. Hassan, MD, FASRS
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more